OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Key facts
- Where
- Brampton, Burlington, Calgary, Cambridge, Chicoutimi, Edmonton, Hamilton, London, Mississauga, Montreal, New Westminster, Newmarket, North York, Oakville, Scarborough Village, Sherbrooke, Surrey, Toronto, Vancouver, and Victoria, CanadaSee the 25 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 105 years old?
Where in Canada
- Centricity Research BramptonBrampton, CanadaTaking people
- Circulate Cardiac & Vascular CentreBurlington, CanadaTaking people
- Centricity Research CalgaryCalgary, CanadaTaking people
- Cambridge Cardiac Care CentreCambridge, CanadaTaking people
- Ecogene-21Chicoutimi, CanadaTaking people
- Edmonton Cardiology ConsultantsEdmonton, CanadaTaking people
- Hamilton Health Sciences - Hamilton General HospitalHamilton, CanadaTaking people
- Premier Clinical Trial NetworkHamilton, CanadaNo longer taking part
- St Josephs HospitalLondon, CanadaTaking people
- Elevate Clinical Research KMH MissisaugaMississauga, CanadaTaking people
- Centre de recherche du Centre hospitalier de l'Université de MontréalMontreal, CanadaTaking people
- Institut de Recherches Cliniques de MontrealMontreal, CanadaTaking people
- Montreal Heart InstituteMontreal, CanadaTaking people
- Research Institute of McGill University Health Center - Glen SiteMontreal, CanadaTaking people
- Fraser Clinical TrialsNew Westminster, CanadaTaking people
- Partners in Advanced Cardiac EvaluationNewmarket, CanadaTaking people
- North York Diagnostic and Cardiac CentreNorth York, CanadaTaking people
- Oakville Cardiovascular ResearchOakville, CanadaTaking people
- Heart Health Institute Research IncorporatedScarborough Village, CanadaTaking people
- CIUSSS de L'Estrie - CHUS - Hopital FleurimontSherbrooke, CanadaTaking people
- SMH Cardiology Clinical Trials IncorporatedSurrey, CanadaTaking people
- Womens College HospitalToronto, CanadaTaking people
- ARC Biosystems IncorporatedVancouver, CanadaTaking people
- Discovery Clinical Services LtdVictoria, CanadaTaking people
- Victoria Heart Institute FoundationVictoria, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07136012
- Record updated
- 21 August 2026
- Original description
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).Read full original descriptionShow less
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Inclusion: Age ≥50 years; Lp(a)≥ 200 nmol/L during screening; Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis.
Exclusion: Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia); Prior or planned arterial revascularization; History of major bleeding disorder.